SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2022 / Cilt: 37 - Sayı: 1

Histopathological and Immunohistochemical Evaluation of 84 Uterine Sarcomas According to Current Literature

Seda DUMAN ÖZTÜRK
Gupse TURAN
Sevgiye KAÇAR ÖZKARA
Pages
51–59
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION Routine use of CD10, h-caldesmon, and cyclin D1 in the histopathological evaluation of US and es tablishing an updated standard checklist was thought to be beneficial for the differential diagnosis and reporting prognostic parameters.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE It was aimed to reevaluate uterine sarcoma cases diagnosed in our institution within the last 20 years according to current information and to provide intra-departmental standardization in the differential diagnosis and reporting.
📊
Key Findings & Data:METHODS Totally 84 uterine sarcoma cases were re-examined.
💡
Conclusion & Impact:CONCLUSION Routine use of CD10, h-caldesmon, and cyclin D1 in the histopathological evaluation of US and es tablishing an updated standard checklist was thought to be beneficial for the differential diagnosis and reporting prognostic parameters.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE It was aimed to reevaluate uterine sarcoma cases diagnosed in our institution within the last 20 years according to current information and to provide intra-departmental standardization in the differential diagnosis and reporting. METHODS Totally 84 uterine sarcoma cases were re-examined. Recurrence, metastasis, and prognostic data were collected from the patient files. Immunohistochemistry panel consisting of CD10, h-caldesmon, and cyclin D1 was applied to the representative tumor tissues. The relationships between the parameters studied were evaluated statistically. RESULTS Statistically significant differences were found between different histopathological types of uterine sar comas (US) in terms of age distribution, tumor diameter, mitotic index, necrosis, depth of myometrial invasion, cervical, adnexial and/or omental involvement, lymphovascular invasion, lymph node metas tasis, recurrence, and distant metastasis. Statistically significant correlation was determined between the prognosis of the patients and mitotic activity of their tumors and the presence of distant metastasis. The immunohistochemistry panel was found to have significant contribution to the histomorphological ex amination in the differential diagnosis. CONCLUSION Routine use of CD10, h-caldesmon, and cyclin D1 in the histopathological evaluation of US and es tablishing an updated standard checklist was thought to be beneficial for the differential diagnosis and reporting prognostic parameters.

🔖

Cite This Article

ÖZTÜRK, S. D., TURAN, G., ÖZKARA, S. K. (2022). Histopathological and Immunohistochemical Evaluation of 84 Uterine Sarcomas According to Current Literature. Türk Onkoloji Dergisi, Cilt: 37 - Sayı: 1, 51–59. https://ajindex.com/articles/639067

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Santos P, Cunha TM. Uterine sarcomas: Clinical presentation and MRI features. Diagn Interv Radiol 2015;21(1):4–9
  2. Barquet-Muñoz SA, Isla-Ortiz D, Montalvo-Esquivel G, Cantú-de-León D, Salcedo-Hernández RA, Cor doba-Gonzalez V, et al. Prognostic factors associated with uterine sarcomas: The experience of a single in stitution. J Obstet Gynaecol 2019;39(2):231–6
  3. El-Khalfaoui K, du Bois A, Heitz F, Kurzeder C, Se- houli J, Harter P. Current and future options in the management and treatment of uterine sarcoma. Ther Adv Med Oncol 2014;6(1):21–8
  4. Fadare O. Heterologous and rare homologous sarco mas of the uterine corpus: A clinicopathologic review. Adv Anat Pathol 2011;18(1):60–74
  5. D’Angelo E, Prat J. Uterine sarcomas: A review. Gynecol Oncol 2010;116(1):131–9
  6. Mallmann P. Uterine sarcoma-difficult to diagnose, hard to treat. Oncol Res Treat 2018;41(11):674
  7. Gao Y, Meng H, Zhang Y, Jiao T, Hui N. Retrospec tive analysis of 80 cases with uterine carcinosar coma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007. Int J Clin Exp Pathol 2014;7(4):1616–24
  8. Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, et al. Uterine leiomyosarcoma: Analy sis of treatment failures and survival. Gynecol Oncol 1996;62(1):25–32
  9. Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG. An evaluation of prognos tic factors in uterine carcinosarcoma. Gynecol Oncol 1997;67(3):316–21. 10.Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nes land JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54(3):355–64. 11.Günthert AR. Sarcomas and mixed mesodermal tu mors of the uterus. Therapeutische Umschau. Ther Umsch 2011;68(10):559–64. 12.Leitao MM Jr., Zivanovic O, Chi DS, Hensley ML, O’Cearbhaill R, Soslow RA, et al. Surgical cytoreduc tion in patients with metastatic uterine leiomyosar coma at the time of initial diagnosis. Gynecol Oncol 2012;125(2):409–13. 13.Larson B, Silfverswärd C, Nilsson B, Pettersson F. Prognostic factors in uterine leiomyosarcoma. A clinical and Histopathological study of 143 cases. The Radiumhemmet series 1936-1981. Acta Oncol 1990;29(2):185–91. 14.Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988;62(10):2239–47. 15.Nordal